HR+/HER2- Breast Cancer Updates



Sonya Reid, MD MPH

Assistant Professor of Medicine Division of Hematology/Oncology Vanderbilt University Medical Center

Outline


Localized breast cancer

1. Serum AMH levels in RxPONDER

Metastatic breast cancer

- 1. INAVO: PFS2, TTFC, PROs results
- 2. postMONARCH
- 3. DESTINY Breast-06

RxPONDER Trial




Kalinsky, et al. NEJM 2021



#ASCO24 PRESENTED BY: Kevin Kalinsky, MD, MS Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org



Chemotherapy benefit differed by menopausal status



*If LMP between 6-12 months and age < 50 years were classified as "premenopausal"

BSO = bilateral salpingo-oophorectomy

2024 ASCO ANNUAL MEETING #ASCO24 PRESENTED BY: Kevin Kalinsky, MD, MS Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org Kalinsky et al. NEJM 2021



Chemotherapy benefit lower in older "premenopausal" in RxPONDER

Subgroup	No. of Participants	No. of Events	Hazard Ratio for Invasive Disease Recurrence, New Primary Cancer, or Death (95% CI)	
Age				
≥50 yr	509	44	0.98 (0.54–1.78	
45–49 yr	615	46	0.46 (0.25–0.86	
<45 yr	531	59	0.49 (0.28–0.84	
Grade				
Intermediate or high	1280	125	0.58 (0.41–0.84	
Low	357	23	0.67 (0.29–1.55	
Tumor size				
T2 or T3	728	80	0.64 (0.41–0.99	
T1	925	69	0.53 (0.32–0.88	
Nodes				
2 or 3 positive	574	55	0.62 (0.36–1.06	
1 positive	1081	94	0.57 (0.37–0.87	
Sentinel node	556	60	0.61 (0.36–1.02	
Full axillary lymph-node dissection	1099	89	0.60 (0.39–0.91	
Recurrence score				
14–25	1015	113	0.63 (0.43–0.91	
0–13	640	36	0.49 (0.24–0.99)
Overall	1655	149	0.60 (0.43–0.83	
			0.50 0.75 1.00 1.50 2.00	
			Chemoendocrine Endocrine Therapy Therapy Better Alone Better	Kalinsky, et al. NEJM 202
PRESENTED BY Kevin Kalinsky	MD MS			



PRESENTED BY: Kevin Kalinsky, MD, MS

2024 ASCO

ANNUAL MEETING

#ASCO24


Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org.

RxPONDER Primary Results

- ✓ Post-menopausal women with 1-3 LN+ and RS ≤ 25 derived no benefit from the addition of chemotherapy to ET
- ✓ "Pre-menopausal" women <55 years with 1-3 LN+ and RS ≤ 25 had an improvement in IDFS and DRFS with the addition of chemotherapy to ET
- Menopausal status is crudely estimated by clinical criteria; is there a role for serologic assays?

Low serum AMH and Inhibin B are markers of diminished ovarian reserve

- Lower Anti-Mullerian hormone (AMH) reflects fewer growing follicles
 - AMH is more stable and reliable during menstrual cycle than estradiol and FSH
 - AMH decreases prior to final menstrual period (*i.e.*, menopause) before FSH elevation
- Inhibin B declines before menopause due to lower follicular number and function



FSH = Follicular Stimulating Hormone

#ASCO24

Bozza C et al Endo-Related Cancer 2014, Moolhuijsen L et al, J Clin Endo Metablism 2020, Wen J et al Front Endo 2021, Nelson P et al Human Reproduction Update 2023



PRESENTED BY: Kevin Kalinsky, MD, MS Presentation is property of the author and ASCO. Permission required for reuse: contact permissions@asco.org



RxPONDER Subgroup analysis

Objective

 To determine chemotherapy benefit if < 55 years using serum markers of ovarian function or reserve

Serum Hormone Levels in Postmenopausal Women					
Low High					
Estradiol	Follicular Stimulating Hormone (FSH)				
Progesterone	Luteinizing Hormone (LH)				
Anti-Mullerian hormone (AMH)					
Inhibin B					






Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org.



Population in this analysis



*Does not include 235 pts < 55 years from UNICANCER who will serve as validation cohort

"Premenopausal": LMP < 6 months or age < 50 years with no LMP > 12 months and no BSO




PRESENTED BY: Kevin Kalinsky, MD, MS Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org.



21% of "premenopausal" women < 55 years had serum AMH in postmenopausal range

Anti-Mullerian hormone



2024 ASCO

#ASCO24

Postmenopausal: < 10 pg/mL (20.6%)

Category (AMH)	Menstrual Category (Final Menstrual Period)	picoAMH (pg/mL)
Low	At FMP or Later	< 10
Medium	< 5 years from FMP	10-99.9
High	> 5 years from FMP	<u>></u> 100

Category	Age < 45	Age 45-49	Age 50-54
Low AMH	10/348	58/397	141/270
	(2.9%)	(14.6%)	(52.2%)

10 pg/ML = 0.01 ng/ML


picoAMH package insert (ELISA) 2023

ASCO^{*} AMERICAN SOCIETY OF CLINICAL ONCOLOGY KNOWLEDGE CONQUERS CANCER

PRESENTED BY: Kevin Kalinsky, MD, MS Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org

"Premenopausal" < 55 years with low AMH have no <u>IDFS</u> benefit with chemotherapy

Low AMH (n=209)



#ASCO24 PRESENTED BY: Kevin Kalinsky, MD, MS Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org

2024 ASCO

ANNUAL MEETING




Medium/High AMH (n=806)

"Premenopausal" < 55 years with low AMH have no <u>DRFS</u> benefit with chemotherapy

Low AMH (n=209)

Medium/High AMH (n=806)



Postmenopausal: < 10 pg/mL

Premenopausal: > 10 pg/mL

Significant interaction p=0.012, adjusting for RS

presented by: Kevin Kalinsky, MD, MS

2024 ASCO

#ASCO24

Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org.



Only AMH predicted chemotherapy benefit

Variable (n=1,016)	Cutoff	Chemo IDFS Benefit*: Variable x Treatment (p-value)
Age	<u>></u> 50 years	0.15
AMH	< 10 pg/mL	0.019*
Inhibin B	<u><</u> 12 pg/mL	0.051
Estradiol	<u><</u> 30 pg/ML	0.88
Progesterone	<u><</u> 0.5 ng/mL	0.78
FSH	>20 mIU/mL	0.13
FSH and Estradiol	> 20 and <u><</u> 30	0.46
LH	> 7 mIU/mL	0.08

*Adjusted for treatment arm, RS, variable and tested the interaction of the variable and treatment for significance (p<0.05) Continuous age, stage, number of nodes, and grade not predictive; AMH and Inhibin B strongly correlated (r=0.74)



#ASCO24

PRESENTED BY: Kevin Kalinsky, MD, MS

Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org.



RxPONDER (SWOG S1007)

- ✓ "Pre-menopausal" women <55 years with 1-3 LN+ and RS ≤ 25 with low AMH levels (< 10pg/ML) did not derive any benefit from the addition of chemotherapy to ET
- ✓ 52.2% of women 50-54 years had low pre-treatment serum AMH
- ✓ AMH was a better predictor of adjuvant chemotherapy benefit than menopause status, age, or other serum hormone levels
- ✓ Low serum AMH could classify who can safely forego adjuvant chemotherapy in women whose menopausal status is unclear

Outline


Localized breast cancer

1. Serum AMH levels in RxPONDER

Metastatic breast cancer

- 1. INAVO: PFS2, TTFC, PROs results
- 2. postMONARCH
- 3. DESTINY Breast-06

HR+/HER2- mBC (PFS benefit)



*Based on data from Phase 3 registrational studies only

#ASCO24

2024 ASCO

ANNUAL MEETING


CDK4/6i, cyclin-dependent kinase 4/6 inhibitor; CT, chemotherapy; ET, endocrine therapy; HER2, human epidermal growth factor receptor 2; HR+, hormone receptor–positive; mBC, metastatic breast cancer; mo, months; mPFS, median progression-free survival; T-DXd, trastuzumab deruxtecan

Finn RS, et al. N Engl J Med. 2016;375;1925–1936; 2. Hortobagyi GN, et al. Ann Oncol. 2018;29:1541–1547; 3. Johnston S, et al. NPJ Breast Cancer. 2019;5:5; 4. Turner NC, et al. N Engl J Med. 2023;388:2058–2070 (Supplementary Appendix);
Bidard FC, et al. J Clin Oncol. 2022;40:3246–3256; 6. O'Shaughnessy J, et al. JAMA Netw Open. 2021;4:e214103; 7. O'Shaughnessy J, et al. Cancer Res. 2021;81(Suppl. 4):Abstract GS4-01; 8. Robert NJ, et al. J Clin Oncol. 2011;29:1252–1260;
Modi S, et al. N Engl J Med. 2022;387:9–20

PRESENTED BY: Giuseppe Curigliano, MD, PhD Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org



INAVO120 study design¹



 An overall bother item: overall bother experienced due to side effects of treatment

* Assessed using grouped terms; severity reported per National Cancer Institute CTCAE version 5.0.[↑] Assessed at D1 of C1–3 then D1 of every other C thereafter (5, 7, 9, etc.), at treatment discontinuation, and every 3 months during survival follow-up; baseline completion rates in both arms were >90% for all assessments; post-baseline rates in both arms remain >80% through C15; <50% intent-to-treat sample remaining at C9 in the inavolisib arm versus C5 in the placebo arm. [‡] Type I error-controlled; hierarchically tested according to a prespecified fixed order of endpoints. [§] Defined as the time from randomization to the first documentation of a ≥2-point increase from baseline on the "worst pain" item held for at least two consecutive Cs, or an initial increase followed by death or treatment discontinuation within 3 weeks from the last assessment. ^{II} A ≥10-point change was defined as a clinically meaningful difference. AE, adverse event; (LA/m)BC, (locally advanced/metastatic) breast cancer; BOR, best overall response; BPI-SF, brief pain inventory-short form; C, Cycle; CBR, clinical benefit rate; CI, confidence interval; CTCAE, Common Terminology Criteria for Adverse Events; ctDNA, circulating tumor DNA; D, Day; DOR, duration of response; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Core Quality of Life questionnaire; ET, endocrine therapy; HER2–, HER2-negative; HR+, hormone receptor-positive; HRQoL, health-related quality of life; ORR, objective response rate; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PFS2, time from randomization to next progression after discontinuing study treatment for PD, or death from any cause; PO, orally; PRO, patient-reported outcomes; Q4W, every 4 weeks; QD, once daily; R, randomized; TTCD, time to confirmed clinical meaningful deterioration.

1. Jhaveri KL, et al. SABCS 2023 (Abstract GS03-13).



95% CI


#ASCO24 PRESENTED BY: Dejan Juric, MD

used to estimate the medians with the Brookmeyer-Crowley method used for the

Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org.



INAVO prolongs PFS in 1st line PIK3CA_{mut} HR+ mBC




CCOD, clinical cutoff date; Cl, confidence interval; Fulv, fulvestrant; HER2–, HER2-negative; HR+, hormone receptor-positive; Inavo, inavolisib; LA/mBC, locally advanced/metastatic breast cancer; OS, overall survival; Palbo, palbociclib; Pbo, placebo; PFS, progression-free survival. 1. Jhaveri KL, *et al.* SABCS 2023 (Abstract GS03-13).

. JIIAVEIT KL, *et al.* SADOS 2023 (ADSITACT 0303-13).



ASCO[®] AMERICAN SOCIETY OF CLINICAL ONCOLOGY KNOWLEDGE CONQUERS CANCER

INAVO120 (PFS2)



Cl, confidence interval; Fulv, fulvestrant; Inavo, inavolisib; NE, not evaluable; Palbo, palbociclib; Pbo, placebo; PFS2, time from randomization to next progression after discontinuing study treatment for disease progression, or death from any cause.




PRESENTED BY: Dejan Juric, MD

Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org.



INAVO120 (TTFC)



Cl, confidence interval; Fulv, fulvestrant; Inavo, inavolisib; NE, not evaluable; Palbo, palbociclib; Pbo, placebo.




#ASCO24 PRESENTED BY: Dejan Juric, MD

Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org.



Safety



* Majority of key selected AEs had resolved ('resolution' was per investigator decision) by the CCOD; some patients were enrolled close to the CCOD and AE follow-up is ongoing for these patients. † Denominators are patients with at least one AE (hyperglycemia, Inavo+Palbo+Fulv: n = 95, Pbo+Palbo+Fulv: n = 14; diarrhea, Inavo+Palbo+Fulv: n = 78, Pbo+Palbo+Fulv: n = 26; rash, Inavo+Palbo+Fulv: n = 41, Pbo+Palbo+Fulv: n = 28; and stomatitis/mucosal inflammation, Inavo+Palbo+Fulv: n = 83, Pbo+Palbo+Fulv: n = 43).

AE, adverse event; CCOD, clinical cutoff date; Fulv, fulvestrant; Inavo, inavolisib; Palbo, palbociclib; Pbo, placebo.




#ASCO24 PRESENTED BY: Dejan Juric, MD

Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org.



Time to confirmed clinical meaningful deterioration in worst pain severity (BPI-SF)

Patients in the inavolisib arm experienced a longer duration of time without confirmed, clinically meaningful worsening pain severity than patients in the placebo arm



BPI-SF, brief pain inventory-short form; CI, confidence interval; Fulv, fulvestrant; Inavo, inavolisib; NE, not evaluable; Palbo, palbociclib; Pbo, placebo.



#ASCO24 PRESENTED BY: Dejan Juric, MD

Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org



INAVO120

- Inavolisib + palbociclib + fulvestrant is a promising option in high risk PIK3CA-mutated, HR+/HER2- mBC who relapsed during/within 12 months of adjuvant ET completion
 - improvement in PFS1 and PFS2
 - delay time to chemotherapy
 - improvement in worst bone pain
- ✓ Inavolisib discontinuation rate was low with manageable safety profile
- ✓ Received breakthrough therapy designation on May 20th, 2024
- ✓ Caveat: Unclear efficacy/toxicity with other CDK4/6i combinations

Outline

Localized breast cancer


1. Serum AMH levels in RxPONDER

Metastatic breast cancer

- 1. INAVO: PFS2, TTFC, PROs results
- 2. postMONARCH
- 3. DESTINY Breast-06

Treatment options after 1L CDK4/6i

- Biomarker driven approach
- Everolimus + ET (if no targetable mutation)
- mPFS with these agents is <6months and toxicities vary






PRESENTED BY: Kevin Kalinsky, MD, MS Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org

Juric D. et al 2019 Proceedings of SABCS 79(4) Abstract nr GS3-08 Oliveira M. et al 2023 Annals of Oncology 8(1) Turner N. et al 2023 N Engl J Med 388(22) 2058-2070 Bidard F. et al 2022 J Clin Oncology 40(28) 3246-32568



postMONARCH Study Design



- Enrolled March 2022 to June 2023 across 96 centers in 16 countries
- Scans every 8 weeks for the first 12 months, then every 12 weeks
- Primary outcome targeted 251 events; interim analysis planned at ~70% of events
- Assuming a hazard ratio (HR) of 0.70, ~80% power to detect abemaciclib superiority, with a cumulative 2-sided type I error of 0.05
- Biomarker ctDNA analyzed by GuardantINFINITY assay

2024 ASCO

#ASCO24 PRESENTED BY: Kevin Kalinsky, MD, MS Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org.



Balanced Baseline Patient & Disease Characteristics

		Abemaciclib + Fulvestrant N=182 (%)	Placebo + Fulvestrant N=186 (%)
Age	Median (range)	58 (27, 86)	61 (28, 85)
	< 65 years	69	63
	\geq 65 years	31	37
Gender	Female	99	100
ECOG	0	57	58
	1	43	43
Region	Other (includes EU)	73	72
	Asia	12	13
	USA	15	15
Race	White	82	82
	Asian	12	15
Bla	ack/African American	4	2
Ethnicity	Not Hispanic/Latino	74	77
	Hispanic/Latino	15	15
HR Status	ER+	100	99
	PR+	79	81

2024 ASCO

ANNUAL MEETING

#ASCO24

PRESENTED BY: Kevin Kalinsky, MD, MS

Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org.


		Abemaciclib + Fulvestrant N=182 (%)	Placebo + Fulvestant N=186 (%)
Measurable Disease		72	68
Visceral metastasis		62	59
Site of Metastasis	Liver	37	38
	Bone-Only	18	23
Prior CDK4/6i Setting	ABC	100	98
	Adjuvant	0	2
Prior CDK4/6i	Palbociclib	59	59
	Ribociclib	34	33
	Abemaciclib	8	8
Prior CDK4/6i Duration	≥12 months [*]	71	77
	<12 months [^]	29	22
	All	19 (2, 110)	21 (3, 87)
Median Prior CDK4/6i	Palbociclib	19	23
Duration (mo; range)#	Ribociclib	15	18
	Abemaciclib	26	21

* \geq 12 months ABC or recurrence after EBC therapy

^ < 12 months ABC or recurrence on EBC therapy # for ABC



Abemaciclib + Fulvestrant prolongs PFS post CDK4/6i + Al



Abemaciclib led to 27% reduction in the risk of developing PFS event



PRESENTED BY: Kevin Kalinsky, MD, MS

Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org.



Investigator-Assessed PFS by Subgroup: Consistent Abemaciclib Effect Across Subgroups

	n	events		HR (95% CI)	Interaction p-value
Overall	368	258	F •	0.73 (0.57, 0.95)	
Age					0.38
<65 years	244 124	173 85	H + + + + + + + + + + + + + + + + + + +	0.79 (0.59, 1.07) 0.63 (0.41, 0.97)	
≥65 years	124	65		0.63 (0.41, 0.97)	0.82
Region Other	267	193		0.71 (0.53, 0.94)	0.82
USA	56	31		0.89 (0.44, 1.80)	
East Asia	45	34		0.80 (0.41, 1.58)	
Measurable Disease	45	54		0.00 (0.41, 1.00)	0.98
Yes	258	192	<u> </u>	0.72 (0.54, 0.95)	0.00
No	110	66		0.71 (0.44, 1.16)	
Visceral Metastasis	110	00		0.71 (0.44, 1.10)	0.07
Yes	221	173		0.87 (0.64, 1.17)	and an and a
No	147	85		0.53 (0.34, 0.83)	
Liver Metastasis				(, , ,	0.40
Yes	139	115	⊢	0.63 (0.44, 0.91)	
No	229	143	⊢	0.78 (0.56, 1.09)	
Bone-Only Disease					0.23
Yes	74	46	⊢ −−−−−−−−−−	0.51 (0.28, 0.95)	
No	294	212	⊢	0.78 (0.59, 1.02)	
PR Status					0.95
Positive	294	201	⊢	0.75 (0.57, 0.99)	
Negative	69	53	⊢ − − − − − − − − − − − − − − − − − −	0.73 (0.43, 1.26)	
Prior CDK4/6i Duration					0.63
ABC ≥12 mo. or after adjuvant CDK4/6i	273	188	⊢	0.70 (0.52, 0.94)	
ABC <12 mo. or during adjuvant CDK4/6i	93	69	⊢	0.80 (0.50, 1.29)	
Prior CDK4/6i					0.19
Palbociclib	217	145		0.62 (0.44, 0.86)	
Ribociclib	122	94	⊢	1.01 (0.67, 1.51)	
Abemaciclib	28	19		0.66 (0.27, 1.64)	

2024 ASCO


#ASCO24

PRESENTED BY: Kevin Kalinsky, MD, MS

Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org.



Subgroup Analysis: Investigator-Assessed PFS by Prior CDK4/6i Duration




2024 ASCO ANNUAL MEETING

#ASCO24

PRESENTED BY: Kevin Kalinsky, MD, MS Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org



Subgroup Analysis: Investigator-Assessed PFS by Visceral Metastasis



No visceral metastasis

Visceral metastasis

#ASCO24 PRESENTED BY: Kevin Kalinsky, MD, MS Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org

2024 ASCO

ANNUAL MEETING

ASCO[®] AMERICAN SOCIETY OL CLINICAL ONCOLOGY KNOWLEDGE CONQUERS CANCER

Exploratory: Consistent Effect Across Biomarker Subgroups

		Abemaciclib + Fulvestrant N=182	Placebo + Fulvestrant N=186
ctDNA Evaluable Population		161 (88%)	159 (85%)
Biomarker Status	ESR1 mutation	40%	51%
	PIK3CA or PTEN or AKT1 alteration	46%	52%

Subgroup	n	events		HR (95% CI)	Interaction p-value
ctDNA Evaluable Population	320	230	F	0.77 (0.59 to 1.00)	
ESR1					0.98
Detected	145	110	F	0.79 (0.54 to 1.15)	
Not detected	175	120	F	0.79 (0.55 to 1.13)	
PIK3CA or AKT1 or PTEN					0.55
Detected	156	118	F = 1	0.86 (0.60 to 1.23)	
Not detected	164	112	⊢ I	0.73 (0.51 to 1.06)	
		0.:	25 0.5 1 2		
			bemaciclib Arm Placebo		
marker ctDNA by GuardantINEINITY assay		P	Demaciciid Arm Placedo	Ann	

Biomarker ctDNA by GuardantINFINITY assay



#ASCO24 PRESENTED BY: Kevin Kalinsky, MD, MS

Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org



Safety Consistent with Known Abemaciclib Profile

	Abemaciclib + Fulvestrant N = 181	Placebo + Fulvestrant N = 185
Grade 5 TRAE⁺, n (%)	1 (0.6)	0
Dose reductions due to AE, n (%)	55 (30)	6 (3)
Discontinuations due to AE, n (%)	11 (6)	0

PRESENTED BY: Kevin Kalinsky, MD, MS

Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org

2024 ASCO

ANNUAL MEETING

#ASCO24

	Abema Fulvestran	ciclib + t, N=181, %	Place Fulvestrant	ebo + t, N=185, %
TEAEs	Any Grade	Grade ≥3	Any Grade	Grade ≥3
Any	97	55	82	20
Diarrhea	75	4	17	2
Neutropenia*	41	25^	3	0
Anemia*	35	11	15	4
Fatigue*	33	3	23	1
Nausea	33	3	18	0
Abdominal Pain*	24	2	16	0
Vomiting	20	2	6	0
Thrombocytopenia*	18	4	6	2
Decreased Appetite	18	1	7	0
Leukopenia*	18	8	3	0
AST Increased	15	6	11	2
ALT Increased	13	4	10	2
Arthralgia	12	1	12	1
Creatinine Increased	11	0	2	0
Cough	11	0	7	0
VTE*	5	2#	3	1
ILD*	3	1§	1	0

+1 Grade 5 treatment-related AE (TRAE) of pneumonia

*Consolidated term

Includes: ^2 Febrile Neutropenia (1 Grade 3; 1 Grade 4), *1 Grade 5 Pulmonary Embolism, [§]1 Grade 3, 1 Grade 4 ILD



postMONARCH

 ✓ 1st Phase III RCT to show benefit of continued CDK4/6i with abemaciclib + fulvestrant following progression on a CDK4/6i

 Greatest benefit seen in patients who received prolonged benefit with 1st line CDK4/6i + ET and w/o visceral metastasis

✓ Safety was consistent with known abemaciclib profile and discontinuation rate was low

Outline


Localized breast cancer

1. Serum AMH levels in RxPONDER

Metastatic breast cancer

- 1. INAVO: PFS2, TTFC, PROs results
- 2. postMONARCH
- 3. DESTINY Breast-06

Trastuzumab Deruxtecan is approved for HER2-low mBC




Adapted with permission from Modi S, et al. J Clin Oncol 2020;38:1887-96. CC BY ND 4.0.



Targeting 'low' and 'ultralow' HER2-expressing tumors in mBC





ASCO/CAP, American Society of Clinical Oncology / College of American Pathologists; HER2, human epidermal growth factor receptor 2; HR+, hormone receptor–positive; IHC, immunohistochemistry; ISH, in situ hybridization; mBC, metastatic breast cancer; T-DXd, trastuzumab deruxtecan

Images adapted from Venetis K, et al. Front Mol Biosci. 2022;9:834651. CC BY 4.0 license available from: https://creativecommons.org/licenses/by/4.0/

1. Wolff AC, et al. J Clin Oncol. 2023;41:3867–3872; 2. Denkert C, et al. Lancet Oncol. 2021;22:1151–1161; 3. Chen Z, et al. Breast Cancer Res Treat. 2023;202:313–323; 4. Mehta S, et al. J Clin Oncol. 2024;42(Suppl. 16):Abstract e13156





Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org.






2024 ASCO

ANNUAL MEETI

Study design

DESTINY-Breast06: a Phase 3, randomized, multicenter, open-label study (NCT04494425)



*Study enrollment was based on central HER2 testing. HER2 status was determined based on the most recent evaluable HER2 IHC sample prior to randomization. HER2-ultralow was defined as faint, partial membrane staining in <10% of tumor cells (also known as IHC >0<1+); [†]HER2-ultralow status as determined per IRT data (note: efficacy analyses in the HER2-ultralow subgroup were based on n=152 as determined per central laboratory testing data); [‡]to be presented separately BICR, blinded independent central review; CDK4/6i, cyclin-dependent kinase 4/6 inhibitor; DOR, duration of response; ET, endocrine therapy; HER2, human epidermal growth factor receptor 2; HR+, hormone receptor–positive; IHC, immunohistochemistry; INV, investigator assessed; IRT, interactive response technology; ISH, in situ hybridization; ITT, intent-to-treat; mBC, metastatic breast cancer; ORR, objective response rate; OS, overall survival; PD, progressive disease; PFS, progression-free survival; Q3W, every 3 weeks; R, randomization; T-DXd, trastuzumab deruxtecan; TPC, chemotherapy treatment of physician's choice NCT04494425. Updated. April 12, 2024. Available from: https://clinicaltrials.gov/study/NCT04494425 (Accessed May 13, 2024)

#ASCO24 PRESENTED BY: Giuseppe Curigliano, MD, PhD

Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org.





Patient demographics and key baseline characteristics

	HER2-low*		ITT (HER2-low and HER2-ultralow)		HER2-ultralow*	
	T-DXd (n=359)	TPC (n=354)	T-DXd (n=436)	TPC (n=430)	T-DXd (n=76)	TPC (n=76)
Age, median (range), years	58.0 (28–87)	57.0 (32–83)	58.0 (28–87)	57.0 (32-83)	58.0 (33-85)	57.5 (34–82)
Female, n (%)	359 (100)	353 (99.7)	436 (100)	429 (99.8)	76 (100)	76 (100)
ECOG PS at screening, n (%) [†]						
0	207 (57.7)	218 (61.6)	252 (57.8)	257 (59.8)	44 (57.9)	39 (51.3)
1	148 (41.2)	128 (36.2)	178 (40.8)	163 (37.9)	30 (39.5)	35 (46.1)
HER2 status, n (%) [‡]						
IHC 0 with membrane staining (HER2-ultralow)	-	-	76 (17.4)	76 (17.7)	76 (100)	76 (100)
IHC 1+ (HER2-low)	238 (66.3)	234 (66.1)	239 (54.8)	234 (54.4)	-	-
IHC 2+/ISH- (HER2-low)	117 (32.6)	118 (33.3)	117 (26.8)	118 (27.4)	-	_
ER/PR status, n (%)§						
ER+/PR+	206 (57.4)	193 (54.5)	253 (58.0)	237 (55.1)	46 (60.5)	44 (57.9)
ER+/PR-	141 (39.3)	152 (42.9)	167 (38.3)	181 (42.1)	26 (34.2)	29 (38.2)
ER-/PR+	3 (0.8)	2 (0.6)	3 (0.7)	2 (0.5)	-	-
Primary endocrine resistance ¹	105 (29.2)	116 (32.8)	128 (29.4)	140 (32.6)	23 (30.3)	24 (31.6)
De-novo disease at diagnosis, n (%)	111 (30.9)	104 (29.4)	133 (30.5)	132 (30.7)	22 (28.9)	28 (36.8)
Bone-only disease at baseline, n (%)	11 (3.1)	10 (2.8)	13 (3.0)	13 (3.0)	2 (2.6)	3 (3.9)
Visceral disease at baseline, n (%)	309 (86.1)	299 (84.5)	376 (86.2)	364 (84.7)	66 (86.8)	65 (85.5)
Liver metastases at baseline, n (%)	243 (67.7)	232 (65.5)	296 (67.9)	283 (65.8)	52 (68.4)	51 (67.1)

*HER2-low status defined at randomization per IRT data, and HER2-ultralow status defined per central laboratory testing data. With mis-stratification, the combined sample size of these two populations may not match the ITT total; ¹n=14 patients had missing ECOG PS status at baseline; ¹n=2 patients in the ITT (1 per treatment group) were found to have HER2 IHC 0 with absent membrane staining per central laboratory testing; [§]patients with ER-/PR- status were excluded from the study; however, n=1 patient with ER-/PR- status was randomized in error; [¶]defined as relapse while on the first 2 years of adjuvant endocrine therapy, or progressive disease within the first 6 months of first-line endocrine therapy for metastatic breast cancer; ECOG PS, Eastern Cooperative Oncology Group performance status; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; IRT, interactive response technology; ISH, in situ hybridization; ITT, intent-to-treat; PR, progesterone receptor; T-DXd, trastuzumab deruxtecan; TPC, chemotherapy treatment of physician's choice

2024 ASCO

#ASCO24

PRESENTED BY: Giuseppe Curigliano, MD, PhD

Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org





Prior therapies

	HER2-low*		ITT (HER2-low and HER2-ultralow)		HER2-ultralow*	
	T-DXd (n=359)	TPC (n=354)	T-DXd (n=436)	TPC (n=430)	T-DXd (n=76)	TPC (n=76)
ET in the metastatic setting						
Lines of ET						
Number of lines, median (range)	2.0 (1-4)	2.0 (1–5)	2.0 (1-4)	2.0 (1–5)	2.0 (1–4)	2.0 (1–5)
Number of lines, n (%)						
1	54 (15.1)	67 (19.0)	65 (14.9)	82 (19.2)	11 (14.5)	15 (19.7)
≤6 months on first-line ET + CDK4/6i	33 (9.2)	33 (9.4)	37 (8.5)	40 (9.3)	4 (5.3)	7 (9.2)
2	242 (67.6)	236 (67.0)	295 (67.8)	288 (67.3)	52 (68.4)	52 (68.4)
≥3	62 (17.3)	49 (13.9)	75 (17.2)	58 (13.6)	13 (17.1)	9 (11.8)
Prior therapies, n (%)						
ET monotherapy	189 (52.6)	183 (51.7)	230 (52.8)	223 (51.9)	41 (53.9)	40 (52.6)
ET with CDK4/6i	318 (88.6)	316 (89.3)	388 (89.0)	385 (89.5)	69 (90.8)	69 (90.8)
ET with other targeted therapy †	120 (33.4)	105 (29.7)	143 (32.8)	127 (29.5)	22 (28.9)	22 (28.9)
Adjuvant/neoadjuvant setting [‡]						
Prior therapies, n (%)						
ET	227 (63.2)	218 (61.6)	275 (63.1)	256 (59.5)	48 (63.2)	38 (50.0)
Cytotoxic chemotherapy	192 (53.5)	196 (55.4)	228 (52.3)	234 (54.4)	36 (47.4)	38 (50.0)
Taxane	151 (42.1)	151 (42.7)	179 (41.1)	177 (41.2)	28 (36.8)	26 (34.2)
Anthracycline	167 (46.5)	173 (48.9)	197 (45.2)	206 (47.9)	30 (39.5)	33 (43.4)

*HER2-low status defined at randomization per IRT data, and HER2-ultralow status defined per central laboratory testing data; [†]other targeted therapies were mTORi (23.8%), PI3Ki (4.2%), or PARPi (0.9%) in the ITT; [‡]approximately 30% of the patient population had de-novo metastatic disease and were not included in this category

CDK4/6i, cyclin-dependent kinase 4/6 inhibitor; ET, endocrine therapy; HER2, human epidermal growth factor receptor 2; IRT, interactive response technology; ISH, in situ hybridization; ITT, intent-to-treat; mTORi, mammalian target of rapamycin inhibitor; PARPi, poly-adenosine diphosphate ribose polymerase inhibitor; PI3Ki, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha inhibitor; T-DXd, trastuzumab deruxtecan; TPC, chemotherapy treatment of physician's choice




#ASCO24

PRESENTED BY: GIUSEPPE Curigliano, MD, PhD

Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org.



T-DxD improves PFS in HER2-low and HER2-ultralow mBC



T-DXd demonstrated a statistically significant and clinically meaningful improvement in PFS compared with standard-of-care chemotherapy in HER2-low

*P-value of <0.05 required for statistical significance

BICR, blinded independent central review, CI, confidence interval; HER2, human epidermal growth factor receptor 2; mo, months; (m)PFS, (median) progression-free survival; T-DXd, trastuzumab derustecan TPC chemotherapy treatment of physician's choice.



DESTINY-Breast06

PRESENTED BY: Giuseppe Curigliano, MD, PhD

entation is property of the author and ASCO. Permission required for reuse: contact pe

ASCO AMERICAN SOCIE CLINICAL ONCOL

#ASCO24 PRESENTED BY: Glusseppe Curigliano, MD, PhD Presentation is property of the author and ASCO. Permission required for reuse: contact of


*P-value of <0.015 required for statistical significance

BICR, blinded independent central review: CI, confidence

ASCO AMERICAN SOCIETY CLINICAL ONCOLOG KNOWLEDGE CONQUERS CANC

DESTINY-Breast06

PFS (BICR) in ITT: key secondary endpoint



T-DXd demonstrated a statistically significant and clinically meaningful improvement in PFS compared with standard-of-care chemotherapy in ITT


mo. months: (m)PFS. (median) progression-free survival: T-DXd. trastuzumab deruxtecan: TPC, chemotherapy treatment of physician's choice

Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.

2024 ASCO



OS in HER2-low and ITT: key secondary endpoints (~40% maturity)



*39.6% maturity (of total N for population) at this first interim analysis; median duration of follow up was 18.6 months (HER2-low); [†]P-value of <0.0046 required for statistical significance; [‡]no test of significance was performed in line with the multiple testing procedure; median duration of follow up was 18.2 months (ITT)

CI, confidence interval; HER2, human epidermal growth factor receptor 2; ITT, intent-to-treat; OS, overall survival; T-DXd, trastuzumab deruxtecan; TPC, chemotherapy treatment of physician's choice



#ASCO24


PRESENTED BY: GIUSEPPE Curigliano, MD, PhD

Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org





PFS and OS in HER2-ultralow: prespecified exploratory analyses



PFS improvement with T-DXd vs TPC in HER2-ultralow was consistent with results in HER2-low

*34.9% maturity (of total N for population) at this first interim analysis; median duration of follow up was 16.8 months BICR, blinded independent central review; CI, confidence interval; HER2, human epidermal growth factor receptor 2; OS, overall survival; mo, months; (m)PFS, (median) progression-free survival; T-DXd, trastuzumab deruxtecan; TPC, chemotherapy treatment of physician's choice

2024 ASCO ANNUAL MEETING

#ASCO24

PRESENTED BY: Giuseppe Curigliano, MD, PhD

Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org.





PFS (BICR) in HER2-low: subgroup analysis

	No. of events / no. of patients mPFS (95% Cl), months					
	T-DXd	TPC	T-DXd	TPC	Hazard ratio (95% CI)
Age					1	
<65 years	158/252	157/244	13.2 (11.2–15.2)	7.8 (6.9-8.6)	H H H	0.59 (0.47-0.74)
≥65 years	67/107	75/110	13.2 (9.7-17.0)	8.5 (6.9-11.5)	⊢ −− −−↓	0.68 (0.49-0.95)
HER2 status*						
IHC 1+	157/238	150/234	12.9 (11.0–15.2)	8.2 (7.1–9.8)	H O H	0.74 (0.59-0.93)
IHC 2+/ISH-	65/117	80/118	15.2 (12.2–21.4)	7.0 (6.2-8.4)	⊢ ●→ !	0.43 (0.31-0.60)
Prior CDK4/6i						
Yes	206/324	212/320	13.1 (11.2-15.2)	7.9 (6.9-8.6)	H O H I	0.61 (0.51-0.74)
No	19/35	20/34	16.1 (9.7–NE)	11.1 (6.9–20.6)		0.64 (0.34-1.21)
Prior taxane use (adjuvant/neoadjuvant setting)						
Yes	94/151	101/151	12.9 (9.7-14.0)	7.4 (6.3-9.3)	⊢ − −+ ¦	0.64 (0.48-0.85)
No	131/208	131/203	15.0 (11.3-16.5)	8.3 (7.0-9.7)		0.59 (0.46-0.76)
Number of prior lines of ET (metastatic setting)					1	
1	27/54	45/67	15.2 (9.7-19.1)	8.0 (5.7-8.5)	⊢	0.45 (0.27-0.72)
2	158/242	153/236	13.1 (11.2-15.2)	8.3 (6.9-10.0)	H +	0.69 (0.55-0.86)
≥3	39/62	33/49	12.3 (8.3-18.5)	8.1 (5.4-9.7)		0.53 (0.33-0.86)
Endocrine resistance						
Primary	66/105	83/116	13.1 (10.0–15.2)	6.8 (5.3-8.1)	⊢ ∎ i	0.56 (0.40-0.78)
Secondary	159/254	148/236	13.2 (11.3–15.5)	9.0 (7.5-11.1)	H O -H	0.65 (0.52-0.82)
Choice of chemotherapy [†]						
Capecitabine	131/220	134/208	13.5 (11.4–15.4)	8.5 (7.0-11.4)	H H	0.62 (0.49-0.79)
Taxanes (Nab-paclitaxel + paclitaxel)	94/139	98/146	12.9 (9.6-15.4)	7.3 (6.4-8.3)		0.62 (0.46-0.82)
Liver metastases						
Yes	163/243	166/232	11.4 (9.8-13.2)	7.0 (6.4-8.1)	H H H	0.58 (0.46-0.72)
No	62/116	66/122	17.0 (15.0–19.4)	11.3 (8.2–14.8)		0.66 (0.46-0.93)
			. , ,			
					0.25 0.5 1 2	

Size of circle is proportional to the number of events

#ASCO24

*Based on central laboratory data (ie the HER2 result from the most recent evaluable sample prior to randomization); †specified by the investigator prior to randomization

BICR, blinded independent central review; CDK4/6i, cyclin-dependent kinase 4/6 inhibitor; CI, confidence interval; ET, endocrine therapy;

HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; ISH, in situ hybridization; (m)PFS, (median) progression-free survival;

NE, not evaluable; T-DXd, trastuzumab deruxtecan; TPC, chemotherapy treatment of physician's choice



PRESENTED BY: GIUSEPPE Curigliano, MD, PhD

Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org.



Favors T-DXd Favors TPC

DESTINY Breast-06

✓ T-DxD demonstrated a statistically significant and clinically meaningful PFS benefit vs. chemotherapy in HR+, HER2-low mBC after ≥ 1L ET

✓ Consistent results also observed in HR+, HER2-ultralow mBC

✓ ~85% of patients with HR+/HER2- mBC eligible for T-DxD
- HER2-low (60-65%) and HER2-ultralow (20-25%)

Key Take Aways (ASCO 2024)

- ✓ In RxPONDER, AMH was a better predictor of adjuvant chemotherapy benefit than menopause status, age, or other serum hormone levels
- Inavolisib + palbociclib + fulvestrant is a promising option in <u>high risk</u> <u>PIK3CA-mutated</u>, HR+/HER2- mBC who relapsed during/within 12 months of adjuvant ET completion
- ✓ The addition of abemaciclib to fulvestrant significantly improved PFS in patients who previously received a CDK4/6i in the 1L setting
- ✓ T-DxD demonstrated a statistically significant and clinically meaningful PFS benefit vs. chemotherapy in HR+, HER2-low mBC after ≥ 1L ET
 - consistent results in the HER2-ultralow cohort

Treatment landscape in HR+/HER2- mBC (2024)

	ET + CDK4/6i
1L	
	ET + CDK4/6i +/- Inavolisib (High-risk, PIK3CAm)

	PIK3CA mutation	Alpelisib + Fulvestrant; Capivarsertib + Fulvestrant				
	AKT1/PTEN alteration	Capivarsertib + Fulvestrant				
2L+	ESR1 mutation	Elacestrant				
	HER2-low, HER2-ultra low*	Trastuzumab Deruxtecan				
		Everolimus + ET				
	No targetable mutation	Switch CDK4/6i + ET				
	HER2-low, HER2-ultra low*	Trastuzumab Deruxtecan				
3L+	HER2 0	Sacituzumab Govitecan	Single-agent Chemotherapy			

gBRCA: PARP inhibitor (2L+)